Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTICIPATE dexrazoxane cardioprotection trial in DLBCL
NL-OMON59125Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexrazoxane in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoints: Incidence of anthracycline-induced cardiac dysfunction and Complete metabolic remission. Started Aug 2024; status: recruiting.
02
Drugs
dexrazoxane
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON59125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59125.